- Lobbying
- b AND lab
Lobbying Arrangements Results for 'B Lab'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Program funding |
UW System CO-Lab
|
BROYDRICK & ASSOCIATES | |||
Details Medicare and perscription drug management. |
AIT
|
FaegreBD Consulting | |||
Details Medicare and Medicaid coverage and payment |
COALITION FOR EXCELLENCE IN MEDICATION MONITORING
|
FaegreBD Consulting | |||
Details Lobbying related to engaging Congress and the Administration on a proposed initiative focused on inclusive economic growth |
B Lab
|
FGS Global (US) LLC (FKA FGH Holdings LLC) | |||
Details Funding for research and coastal habitat recovery Gulf of Mexico oil spill impacts |
Dauphin Island Sea Lab
Estuary, Coastal, and Fisheries Research |
The Mita Group, Inc. | |||
Details Provide assistance related to health data issues. |
IMS Government Solutions, Inc.
|
Barbour Griffith & Rogers, LLC d/b/a BGR Holding | |||
Details Health Care Reform Legislation; PPACA |
Revere America
|
Barbour Griffith & Rogers, LLC d/b/a BGR Holding | |||
Details Provide advice, counsel, and as appropriate direct advocacy services related to public policies impacting the biopharmaceutical industry generally, and Pernixs priorities and product portfolio spec... |
Pernix Therapeutics
|
BGR Government Affairs | |||
Details Provide guidance and strategic counsel on federal regulatory policy and legislative issues affecting Chelsea's products. |
Chelsea Therapeutics
|
Barbour Griffith & Rogers, LLC d/b/a BGR Holding | |||
Details Health Care Reform Legislation; Provide gudiance and strategic counsel on energy related issues |
Partnership for America
|
Barbour Griffith & Rogers, LLC d/b/a BGR Holding | |||
Details Provide gudiance and strategic counsel on Special Needs Plans with Medicare; Medicare Advantage risk adjustment and new enrollee model. |
XL HEALTH
|
Barbour Griffith & Rogers, LLC d/b/a BGR Holding | |||
Details Provide guidance and strategic counsel with regard to DEA scheduling of FDA approved products. |
DEA Scheduling Coalition (Informal Coalition)
|
BGR Government Affairs | |||
Details Patient Protection and Affordable Care Act (PPACA) implementation issues; Budget Control Act of 2011; Sustainable Growth Rate reform; Medicare reimbursement and beneficiary cost-sharing for Clini... |
Caris Science, Inc.
|
in-house lobbying | |||
Details Health reform implementation; health exchanges and essential benefits; DOC Access Act |
National Association of Vision Care Plans
|
BGR Government Affairs | |||
Details Monitor, advise, and as appropriate directly advocate on healthcare and tax policy issues related to Allergan specifically and the lifesciences industry generally. |
Allergan, Inc.
|
Barbour Griffith & Rogers, LLC d/b/a BGR Holding | |||
Details Provide guidance and strategic counsel with regard to pending healthcare legislation and the potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C pol... |
Gilead Sciences, Inc.
|
BGR Government Affairs | |||
Details Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Merck specifically |
Merck & Co., Inc.
|
BGR Government Affairs | |||
Details Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally, and/ Celgene specifically |
Celgene Corporation
|
BGR Government Affairs | |||
Details Health IT; physician fee schedule update; implementation of health care reform; state exchanges; third party payer exchanges |
AAPAN
|
BGR Government Affairs | |||
Details Provide guidance and strategic counsel with regard to regulations and legislation that could impact, pharmaceutical and biotechnology manufacturers. |
Genentech, Inc.
|
BGR Government Affairs | |||
Details Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biotechnology industry |
Sanofi US Services, Inc.
|
BGR Government Affairs | |||
Details H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.162... |
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION
|
ALPINE GROUP, INC. | |||
Details Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and Zogenix specifically. |
Zogenix, Inc.
|
BGR Government Affairs | |||
Details Patent reform; Medicare Part-D non-interference legislation; Medicaid rebates; Follow-on biologics; implementation of health care reform; PDUFA; FDA reform; Trade issues |
Eli Lilly & Co, Inc.
|
BGR Government Affairs | |||
Details Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically |
Alkermes, Inc.
Biopharmaceutical company |
BGR Government Affairs | |||
Details Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
PFIZER, INC
|
BGR Government Affairs | |||
Details Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration. |
Pharmaceutical Research and Manufacturers of America
|
BGR Government Affairs | |||
Details Issues related to international investments |
Silver Point Capital
|
Hogan Lovells US LLP | |||
Details Provide guidance and counsel with regard to federal medical device policy and regulatory issues and reimbursement issues within Medicare program, including IPPS Regulation, and FDA regulatory policy. |
Abiomed Inc.
|
BGR Government Affairs | |||
Details Issues related to live event ticketing industry; TICKET ACT (S.1303 / H.R. 3950), all provisions relating to transparency, speculative ticketing, and competition issues; Fans First Act (S.3457), al... |
Anschutz Entertainment Group Inc.
|
Hogan Lovells US LLP | |||
Details FDA modernization policy issues Reauthorization of newborn screening programs General issues related to rare disease and orphan drugs General issues related to health equity in rare disease and ... |
AstraZeneca Pharmaceuticals LP
|
in-house lobbying | |||
Details Issue: Support research with non-human primates Presidents FY 2024 Budget Request S.2624 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act,... |
Association of American Medical Colleges
|
in-house lobbying |